• John C Somberg and Janos Molnar.
• American Institute of Therapeutics, Lake Bluff, IL.
• Am J Ther. 2015 May 1;22(3):214-21.

AbstractTreatment of chronic pain in diabetic neuropathy or neuropathic pain of other origins is challenging. Compounded topical formulations have evolved as potential treatment options. The objective of this retrospective study was to evaluate the efficacy of a compounded topical cream (Transdermal Therapeutics). Two versions of TT-CTAC cream were evaluated: cream 6B and cream 7B. Both creams contain ketamine (10%), baclofen (2%), gabapentin (6%), amitriptyline (4%), bupivacaine (2%), and clonidine (0.2%). Additionally, one cream (7B) contains nifedipine (2%). The primary efficacy outcome was the change in numeric pain intensity score from pretreatment to posttreatment. Secondary outcomes were qualitative grading (excellent, good, poor, or no effect), reduction in oral medication, and avoiding referral to a pain specialist. Information on 283 patients was evaluated, 205 received the 7B and 78 received 6B creams. The pain score decreased by 2.4 ± 2.4 (35%) with the 6B cream (from 7.8 ± 1.6 to 5.4 ± 2.0, P < 0.001) and by 3.0 ± 2.4 (40%) with the 7B cream (from 7.5 ± 1.7 to 4.5 ± 2.2, P < 0.001). Excellent or good effects were reported in 82% of the patients in the 6B and in 70% in the 7B groups. Reduction in oral pain medication was seen in 35% of the patients in the 7B and in 20% in the 6B groups. In the opinion of the treating physicians, the cream therapy caused the avoidance of a pain specialist referral in 53% of the patients in the 6B and in 39% in the 7B groups. The creams were equally effective in diabetic neuropathy, neuropathic pain, or other chronic pain states. We conclude that both creams provided excellent pain relief in the majority of the patients studied and may be a useful modality for pain therapy.

15 keywords...

hide…